NAVCO Pharmaceuticals Inc.
NAVCO Pharmaceuticals Inc. develops and commercializes supplemental and therapeutic consumer health and wellness products in the areas of antibacterial and immunity support and infectious disease prevention in Canada. The company offers aerosol sprays, hand cleansers, hand creams, and nano bioguard; and disinfectant spray products. It also provides diagnostic testing, textile, PPE, and food solut… Read more
NAVCO Pharmaceuticals Inc. (F0U) - Net Assets
Latest net assets as of : €- EUR
Based on the latest financial reports, NAVCO Pharmaceuticals Inc. (F0U) has net assets worth €- EUR as of .
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€-) and total liabilities (€-). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €- |
| % of Total Assets | 0% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | N/A |
NAVCO Pharmaceuticals Inc. - Net Assets Trend (None–None)
This chart illustrates how NAVCO Pharmaceuticals Inc.'s net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for NAVCO Pharmaceuticals Inc. (None–None)
The table below shows the annual net assets of NAVCO Pharmaceuticals Inc. from None to None.
| Year | Net Assets | Change |
|---|---|---|
| No yearly data available. | ||
Equity Component Analysis
This analysis shows how different components contribute to NAVCO Pharmaceuticals Inc.'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- No equity composition insights available.
NAVCO Pharmaceuticals Inc. Competitors by Market Cap
The table below lists competitors of NAVCO Pharmaceuticals Inc. ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Origin Investment Corp I
NASDAQ:ORIQ
|
$97.99K |
|
Karbon Capital Partners Corp. Units
NASDAQ:KBONU
|
$98.00K |
|
Terna SpA
MU:UEI
|
$98.05K |
|
THQQD
PINK:THQQD
|
$98.07K |
|
Principal Real Estate Income Closed Fund
NYSE:PGZ
|
$97.95K |
|
140610
KO:140610
|
$97.95K |
|
Praetorian Acquisition Corp. Units
NASDAQ:PTORU
|
$97.94K |
|
Clearmind Medicine Inc. Common Shares
NASDAQ:CMND
|
$97.90K |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in NAVCO Pharmaceuticals Inc.'s equity between the two most recent reporting periods.
Insufficient data available to analyze equity growth attribution.
Book Value vs Market Value Analysis
This analysis compares NAVCO Pharmaceuticals Inc.'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Insufficient data available to analyze book value vs market value.
Capital Efficiency Dashboard
This dashboard shows how efficiently NAVCO Pharmaceuticals Inc. utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Insufficient data available to analyze capital efficiency metrics.
Industry Comparison
This section compares NAVCO Pharmaceuticals Inc.'s net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $9,244,379,027
- Average return on equity (ROE) among peers: -92.52%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| NAVCO Pharmaceuticals Inc. (F0U) | €- | N/A | N/A | $97.98K |
| 26U (26U) | $6.75 Million | -514.32% | 1.08x | $248.33K |
| 27N0 (27N0) | $11.56 Million | -0.93% | 0.00x | $4.66K |
| China Resources Pharmaceutical Group Limited (640) | $90.18 Billion | 4.60% | 1.68x | $940.63 Million |
| CIG WIRELESS (6CW) | $27.09 Million | -110.19% | 3.19x | $56.65 Million |
| Solasia Pharma K.K (9SO) | $1.16 Billion | -167.91% | 0.18x | $34.42 Million |
| Apontis Pharma AG (APPH) | $3.46 Million | -34.21% | 7.59x | $11.70 Million |
| Akebia Therapeutics Inc (AX9) | $635.93 Million | -22.58% | 0.57x | $283.56 Million |
| Biofrontera AG (B8FK) | $-12.89 Million | 0.00% | 0.00x | $3.86 Million |
| AVALA RES (CVJ) | $91.87 Million | -27.32% | 0.11x | $113.22K |
| Deciphera Pharmaceuticals Inc (D05) | $341.69 Million | -52.37% | 0.33x | $2.11 Billion |